Discriminant validity, responsiveness and reliability of the arthritis-specific Work Productivity Survey assessing workplace and household productivity in patients with psoriatic arthritis

Table 1 Baseline demographics and clinical characteristics (randomized set, observed cases)

	All randomized patients (n = 409)
Demographic characteristics
Age (years)	47.6 ± 11.4
Sex (% female)	55.3
Race (% white)	97.8
Weight (kg)	84.4 ± 18.8
Body mass index (kg/m²)	29.8 ± 6.5
Arthritis characteristics
Time from psoriatic arthritis diagnosis^a (years)	8.6 ± 8.2
C-reactive protein^b (mg/l)	8.0 (0.1 to 238.0)
Mean tender joint count (0 to 68 joints)	20.3 ± 14.9
Mean swollen joint count (0 to 66 joints)	10.7 ± 8.0
Physician’s Assessment of Disease Activity, by VAS (mm)	57.9 ± 18.6
Patient’s Assessment of Disease Activity	59.1 ± 20.7
Patient’s Assessment of Arthritis Pain, by VAS (mm)	60.3 ± 20.4
DAS28 (CRP)	5.0 ± 1.0
Mean HAQ-DI (range 0 to 3)	1.31 ± 0.64
Psoriasis characteristics
Psoriasis BSA ≥3% (%)	61.6
PASI^c	11.7 ± 11.9
Prior use of synthetic DMARDs (%)	50.6
1	47.2
≥2
Prior TNF inhibitor exposure (%)	19.6
Health-related quality of life
Mean SF-36 MCS	41.7 ± 12.1
Mean SF-36 PCS	33.4 ± 7.7
Mean PsAQoL	11.1 ± 5.6
Mean DLQI	8.5 ± 7.2
Mean EQ-5D VAS	49.9 ± 20.4

Data presented as mean ± SD, percentage or median (minimum to maximum). BSA, body surface area; DAS28(CRP), Disease Activity Score – 28-joint count based on C-reactive protein; DLQI, Dermatology Life Quality Index; DMARD, disease-modifying antirheumatic drug; EQ-5D, EuroQoL-5 dimensions; HAQ-DI, Health Assessment Questionnaire – Disability Index; MCS, mental component summary; PASI, Psoriasis Area and Severity Index; PCS, physical component summary; PsAQoL, Psoriatic Arthritis Quality of Life; SF-36, Short Form-36 items; TNF, tumor necrosis factor; VAS, visual analogue scale. ^aFrom the start date of the primary disease. ^bNormal range < 8.0 mg/l. ^cPASI scores are presented for patients with psoriasis body surface area ≥ 3% at baseline.

ISSN: 1478-6362